Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Science 37, Crinetics and Gritstone Bio announce inducement grants to boost talent acquisition

By Brian Buntz | April 10, 2023

Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology on laboratory background.

[ipopba/Adobe Stock]

Science 37 Holdings (Nasdaq:SNCE), Crinetics Pharmaceuticals (Nasdaq: CRNX) and Gritstone Bio (Nasdaq:GRTS) have announced recent inducement grants to attract new non-executive employees under Nasdaq Listing Rule 5635(c)(4). This move showcases the companies’ focus on talent acquisition and retention in the competitive pharmaceutical and biotechnology markets.

A clinical trial research organization based in Durham, North Carolina, Science 37 announced today that its compensation committee signed off on inducement equity awards. In all, the company granted options to purchase an aggregate of 110,800 shares of its common stock at an exercise price of $0.29 per share to three new employees. The options have a 10-year term and a four-year vesting schedule.

Grants for Critics and Gritstone

The clinical-stage pharma firm Crinetics Pharmaceuticals specializing in rare endocrine diseases and endocrine-related tumors also announced today that the compensation committee of its board granted non-qualified stock option awards to purchase an aggregate of 311,700 shares of its common stock. The awards will be used for 15 new non-executive employees.

The vaccine-focused biotech Gritstone Bio also announced that its compensation committee of its board granted a single employee nonqualified stock options to purchase an aggregate of 20,000 shares of its common stock with an exercise price of $2.76 on April 3, 2023. The stock options are part of an inducement material to the new employee becoming an employee of Gritstone.

In 2021, Gritstone announced that it was studying its second-generation COVID-19 vaccine in a phase 1 study.  A summary published in Open Forum Infectious Diseases was positive.

Crinetics Pharmaceuticals’ and Gritstone Bio’s stock options will vest over a four-year period.

Other pharma and biotech companies also announce inducement grants

Other companies recently announcing inducement grants include the biopharma Syndax Pharmaceuticals (Nasdaq:SNDX) and  the uro-oncology firm UroGen Pharma (Nasdaq:URGN).

Inducement grants gained in popularity in the late 1990s and early 2000s during the dot-com boom, when technology companies competed fiercely for talent to help drive growth.

Industries relying on inducement grants include the tech sector, pharma and biotech industries, where, traditionally, demand for highly skilled talent is high. Drug developers sometimes include inducement grants in their pay packages to secure specialized talent.


Filed Under: Drug Discovery and Development
Tagged With: biotechnology industry, Crinetics Pharmaceuticals, employee retention, Gritstone Bio, inducement grants, pharmaceutical industry, Science 37, talent acquisition
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE